Mucinex knocked Vicks off the top spot for monthly TV ad impressions as pharma brands generated significant coverage from ...

AbbVie’s Skyrizi was responsible for the highest TV advertising outlay in pharma in most months of 2024, but 2025 is starting ...

It was a busy week for the biotech sector as the fourth-quarter earnings season kicked in. While Regeneron REGN gained following the announcement, Amgen AMGN was in the red. Meanwhile, other pipeline ...

(Reuters) - Regeneron (NASDAQ: REGN) Pharmaceuticals beat fourth-quarter sales and profit estimates on Tuesday, on continuing ...

Enrollment of Part A completed ahead of schedule and exceeded enrollment target with 123 patients enrolledPart A 16-week proof-of-concept data ...

Sanofi SA (SNY) reports robust sales growth driven by Dupixent and vaccines, while planning a significant share buyback to ...

Looking ahead, Sanofi has announced an ambitious share buyback program worth 5 billion euros for 2025, signaling strong confidence in its future prospects. The company projects mid to high ...

Dupixent continues leading among Sanofi’s portfolio, and it’s poised for up to $20 billion in peak sales. Read my SNY ...

Pipeline: Blockbuster anti-inflammatory drug Dupixent--a key growth driver developed jointly by Sanofi and Regeneron Pharmaceuticals--is expected to get a boost from ongoing U.S. prescription growth.

new shops and products, travel destinations, art and cultural events, celebrity style, and high-end real estate as well as access to print features and images from the AD archives.

Netflix has introduced a new type of extra member account: extra members with ads. The streamer announced the new offering in a shareholder letter on Tuesday before its fourth-quarter earnings call.

Rinvoq's total estimated spending came in about $40 million behind Skyrizi's total last year, according to iSpot.TV, while Dupixent's total ... $223 million behind six ads—half in major ...